首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
【24h】

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.

机译:苯并双(亚甲基)连接的双氮杂大环化合物的合成及其构效关系,通过对趋化因子受体CXCR4的拮抗作用抑制HIV-1和HIV-2复制。

获取原文
获取原文并翻译 | 示例
           

摘要

Bis-tetraazamacrocycles such as the bicyclam AMD3100 are a class of potent and selective anti-HIV-1 and HIV-2 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the co-receptor for entry of X4 viruses. With the aim of optimizing the anti-HIV-1 and HIV-2 activity of bis-azamacrocycles, a series of analogues were synthesized which contain neutral heteroatom (oxygen, sulfur) or heteroaromatic (of lower pK(a) than a secondary amine) replacements for the amino groups of AMD3100. The introduction of one or more heteroatoms such as oxygen or sulfur into the macrocyclic ring of p-phenylenebis(methylene)-linked dimers (to give N(3)X or N(2)X(2) bis-macrocycles) gave analogues with substantially reduced anti-HIV-1 (III(B)) and anti-HIV-2 (ROD) potency. In addition, the bis-sulfur analogue was also markedly more cytotoxic to MT-4 cells. However, bis-tetraazamacrocycles featuring a single pyridine group incorporated within the macrocyclic framework exhibited anti-HIV-1 and HIV-2 potency comparable to that of their saturated, aliphatic counterparts. The p-phenylenebis(methylene)-linked dimer of the py[14]aneN(4) macrocycle inhibited HIV-1 replication at a 50% effective concentration (EC(50)) of 0.5 microM while remaining nontoxic to MT-4 cells at concentrations approaching 200 microM. A series of analogues containing macrocyclic heteroaromatic groups of varying pK(a) were also synthesized, and their ability to inhibit HIV replication was evaluated. Replacing the pyridine moiety of the py[14]aneN(4) macrocyclic ring with pyrazine or pyridine groups substituted in the 4-position (with electron-withdrawing or -donating groups) either reduced antiviral potency or increased cytotoxicity to MT-4 cells. Finally, we synthesized a series of analogues in which the ring size of the bis-pyridyl macrocycles was varied between 12 and 16 members per ring including the py[iso-14]aneN(4) ring system, an isomer of the py[14]aneN(4) macrocycle. The p-phenylenebis(methylene)-linked dimer of the py[iso-14]aneN(4) (AMD3329) displayed the highest antiviral activity of the bis-azamacrocyclic analogues reported to date, exhibiting EC(50)'s against the cytopathic effects of HIV-1 and HIV-2 replication of 0.8 and 1.6 nM, respectively, that is, about 3-5-fold lower than the EC(50) of AMD3100. AMD3329 also inhibited the binding of a specific CXCR4 mAb and the Ca(2+) flux induced by SDF-1alpha, the natural ligand for CXCR4, more potently than AMD3100. Furthermore, AMD3329 also interfered with virus-induced syncytium formation at an EC(50) of 12 nM.
机译:Bis-tetraazamacrocycles,例如bicyclam AMD3100,是一类有效的和选择性的抗HIV-1和HIV-2药剂,它们通过结合趋化因子受体CXCR4(X4病毒进入的共同受体)而抑制病毒复制。为了优化双氮杂双环类化合物的抗HIV-1和HIV-2活性,合成了一系列类似物,这些类似物包含中性杂原子(氧,硫)或杂芳香族(pK(a)比仲胺低)替代AMD3100的氨基。将一个或多个杂原子(例如氧或硫)引入对亚苯基双(亚甲基)连接的二聚体的大环中(生成N(3)X或N(2)X(2)双大环),得到类似物大大降低了抗HIV-1(III(B))和抗HIV-2(ROD)的效力。另外,双硫类似物对MT-4细胞也具有明显的细胞毒性。然而,具有掺入大环骨架中的单个吡啶基团的双-四氮杂大环化合物显示出与其饱和的脂族对应物相当的抗HIV-1和HIV-2效能。 py [14] aneN(4)大环的对亚苯基双(亚甲基)连接的二聚体在50%有效浓度(EC(50))为0.5 microM的情况下抑制HIV-1复制,同时对MT-4细胞保持无毒。浓度接近200 microM。还合成了一系列包含不同pK(a)大环杂芳族基团的类似物,并评估了它们抑制HIV复制的能力。用在4位上取代的吡嗪或吡啶基团(具有吸电子或供电子基团)取代py [14] aneN(4)大环的吡啶部分,降低的抗病毒效力或对MT-4细胞的细胞毒性增加。最后,我们合成了一系列类似物,其中双吡啶大环的环大小在每环12至16个成员之间变化,包括py [iso-14] aneN(4)环系统,即py [14的异构体] aneN(4)宏周期。 py [iso-14] aneN(4)(AMD3329)的对亚苯基双(亚甲基)连接的二聚体显示了迄今为止报道的双氮杂大环类似物的最高抗病毒活性,表现出针对细胞病变的EC(50)。 HIV-1和HIV-2复制的影响分别为0.8和1.6 nM,即比AMD3100的EC(50)低约3-5倍。 AMD3329还比AMD3100更有效地抑制特异性CXCR4 mAb和SDF-1alpha(CXCR4的天然配体)诱导的Ca(2+)流量的结合。此外,AMD3329还以12 nM的EC(50)干扰病毒诱导的合胞体形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号